# SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
Canonical URL: https://biopharmsignal.com/news/SERA/sera-prognostics-reports-first-quarter-2026-financial-results
Ticker: SERA
Company: Sera Prognostics
Source: Sera Prognostics
Published: 2026-05-06 20:05 EST
Original Source URL: https://investors.seraprognostics.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-09 20:05 EST — [PRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE](https://biopharmsignal.com/news/SERA/prime-subgroup-analysis-demonstrates-22-reduction-in-nicu-admissions-in-first-ti-1eec527c) — Source: Sera Prognostics
- 2026-06-30 20:05 EST — [SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-appointment-of-mark-capone-to-its-board-of-directors-8cc61214) — Source: Sera Prognostics
- 2026-06-24 20:05 EST — [SERA PROGNOSTICS COLLABORATES ON ARPA-H AWARD TO ADVANCE POINT-OF-CARE DIAGNOSTIC FOR SAFER BIRTH](https://biopharmsignal.com/news/SERA/sera-prognostics-collaborates-on-arpa-h-award-to-advance-point-of-care-diagnosti-7f391c59) — Source: Sera Prognostics
- 2026-06-23 20:05 EST — [SERA APPLAUDS ILLINOIS INITIATIVE TO EXPAND MEDICAID COVERAGE FOR PROTEOMIC BLOOD TESTING IN PREGNANCY](https://biopharmsignal.com/news/SERA/sera-applauds-illinois-initiative-to-expand-medicaid-coverage-for-proteomic-bloo-969662d4) — Source: Sera Prognostics
- 2026-06-01 20:05 EST — [SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-board-transition) — Source: Sera Prognostics
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)